Colon cancer: RFA-Radio Frequency Ablation in metastatic colon cancer study recommended for especially after analysis of various studies. Article update 25 January 2012
This article is a few hours worked. Look up, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
25 January 2012: Dutch study results confirm the results below, all from 2005. Click here for article about Dutch study or read the below article.
18 May 2005: source: British Journal of Cancer (2005) 92, 1825-1829.
doi: 10.1038/6602582 Published online 3 sj. bjc. May 2005
Author of Radio Frequency Ablation to study recommends RFA for different types of solid tumors with emphasis on levertumoren. The author of this study published in The British Journal of Oncology, not one of the least medical journals in the world – indicates that of the people with liver tumors treated with RFA fetches almost 50% a median 5 year survival after start of the RFA. The author also notes that a combination of systemic chemo or local chemotherapy with RFA to a desired and good treatment for colon cancer with setting uitzaaiïngen in the liver and lymph nodes. This again calls for the approach that Dr. Vogl stands for and run successfully because he does not much different than where possible with RFA-LITT evict and further he works with local tumors injected chemo and/or systemic chemo or combination of both.
Here is the abstract of the study to RFA:
The use of radiofrequency in cancer
A R Gillams1
Correspondence to: Dr A Gillams, E-mail: a.gillams@medphys.ucl.ac.uk
Received 18 February 2005; accepted 18 March 2005; published online 3 May 2005
Radiofrequency ablation (RFA) provides an effective technique for minimally invasive tissue destruction. An alternating current delivered via a needle electrode causes agitation and frictional heating of the localised ionic tissue around the needle. Image-guided, percutaneous ablation techniques have been developed in most parts of the body, but the most widely accepted applications are hepatocellular carcinoma (HCC) for the treatment of cirrhosis in early colorectal liver metastases, limited but inoperable renal cell carcinoma and inoperable primary inoperable, or secondary lung tumours. The procedures are well tolerated and the complication rates low. Patients with coexistent morbidity who are not suitable for surgery are often able to undergo RFA. Most treatments in the lung, kidney and for HCC are performed under conscious sedation with an overnight hospital stay or as a day-case. Larger more complicated ablations, for example, in hepatic metastases may require general anaesthesia. Limitations or RFA include the volume of tissue that can be ablated in a timely fashion, that is, most centres will treat tumours 3-5 up to 4-5 cms in diameter. Early series reporting technical success and complications are available for lung and renal ablation. Liver ablation is better established and 5-year survival figures are available from several centres. In patients with inoperable colorectal metastases, but the limited 5-year survival ranges from 26 to 30% and for HCC it is just under 50%. In summary, RFA provides the opportunity for localised tissue destruction or limited volumes or tumour; it can be offered to nonsurgical candidates and used in conjunction with systemic therapy.
